Bradycardia	0	11	O
-	11	12	O
induced	12	19	O
coronary	20	28	B-Multi-tissue_structure
angiogenesis	29	41	O
is	42	44	O
dependent	45	54	O
on	55	57	O
vascular	58	66	B-Gene_or_gene_product
endothelial	67	78	I-Gene_or_gene_product
growth	79	85	I-Gene_or_gene_product
factor	86	92	I-Gene_or_gene_product
.	92	93	O

A	95	96	O
marked	97	103	O
coronary	104	112	B-Multi-tissue_structure
angiogenesis	113	125	O
is	126	128	O
known	129	134	O
to	135	137	O
occur	138	143	O
with	144	148	O
chronic	149	156	O
bradycardia	157	168	O
.	168	169	O

We	170	172	O
tested	173	179	O
the	180	183	O
hypothesis	184	194	O
that	195	199	O
vascular	200	208	B-Gene_or_gene_product
endothelial	209	220	I-Gene_or_gene_product
growth	221	227	I-Gene_or_gene_product
factor	228	234	I-Gene_or_gene_product
(	235	236	O
VEGF	236	240	B-Gene_or_gene_product
)	240	241	O
,	241	242	O
an	243	245	O
endothelial	246	257	B-Cell
cell	258	262	I-Cell
mitogen	263	270	O
and	271	274	O
a	275	276	O
major	277	282	O
regulator	283	292	O
of	293	295	O
angiogenesis	296	308	O
,	308	309	O
is	310	312	O
upregulated	313	324	O
in	325	327	O
response	328	336	O
to	337	339	O
low	340	343	O
heart	344	349	B-Organ
rate	350	354	O
and	355	358	O
consequential	359	372	O
increased	373	382	O
stroke	383	389	O
volume	390	396	O
.	396	397	O

Bradycardia	398	409	O
was	410	413	O
induced	414	421	O
in	422	424	O
rats	425	429	B-Organism
by	430	432	O
administering	433	446	O
the	447	450	O
bradycardic	451	462	O
drug	463	467	O
alinidine	468	477	B-Drug_or_compound
(	478	479	O
3	479	480	O
mg	481	483	O
/	483	484	O
kg	484	486	O
body	487	491	O
weight	492	498	O
)	498	499	O
twice	500	505	O
daily	506	511	O
.	511	512	O

Heart	513	518	O
rate	519	523	O
decreased	524	533	O
by	534	536	O
32	537	539	O
%	539	540	O
for	541	544	O
20	545	547	O
to	548	550	O
40	551	553	O
minutes	554	561	O
after	562	567	O
injection	568	577	O
and	578	581	O
was	582	585	O
chronically	586	597	O
reduced	598	605	O
by	606	608	O
10	609	611	O
%	611	612	O
,	612	613	O
14	614	616	O
%	616	617	O
,	617	618	O
and	619	622	O
18	623	625	O
.	625	626	O
5	626	627	O
%	627	628	O
after	629	634	O
1	635	636	O
,	636	637	O
2	638	639	O
,	639	640	O
and	641	644	O
3	645	646	O
weeks	647	652	O
of	653	655	O
treatment	656	665	O
,	665	666	O
respectively	667	679	O
.	679	680	O

Arterial	681	689	B-Multi-tissue_structure
pressure	690	698	O
and	699	702	O
cardiac	703	710	O
output	711	717	O
were	718	722	O
unchanged	723	732	O
.	732	733	O

Left	734	738	B-Tissue
ventricular	739	750	I-Tissue
capillary	751	760	I-Tissue
length	761	767	O
density	768	775	O
(	776	777	O
mm	777	779	O
/	779	780	O
mm	780	782	O
(	782	783	O
3	783	784	O
)	784	785	O
)	785	786	O
increased	787	796	O
gradually	797	806	O
with	807	811	O
alinidine	812	821	B-Drug_or_compound
administration	822	836	O
;	836	837	O
a	838	839	O
15	840	842	O
%	842	843	O
increase	844	852	O
after	853	858	O
2	859	860	O
weeks	861	866	O
and	867	870	O
a	871	872	O
40	873	875	O
%	875	876	O
increase	877	885	O
after	886	891	O
3	892	893	O
weeks	894	899	O
of	900	902	O
alinidine	903	912	B-Drug_or_compound
treatment	913	922	O
were	923	927	O
documented	928	938	O
.	938	939	O

Left	940	944	B-Multi-tissue_structure
ventricular	945	956	I-Multi-tissue_structure
weight	957	963	O
,	963	964	O
body	965	969	O
weight	970	976	O
,	976	977	O
and	978	981	O
their	982	987	O
ratio	988	993	O
were	994	998	O
not	999	1002	O
significantly	1003	1016	O
altered	1017	1024	O
by	1025	1027	O
alinidine	1028	1037	B-Drug_or_compound
treatment	1038	1047	O
.	1047	1048	O

After	1049	1054	O
1	1055	1056	O
week	1057	1061	O
of	1062	1064	O
treatment	1065	1074	O
,	1074	1075	O
before	1076	1082	O
an	1083	1085	O
increase	1086	1094	O
in	1095	1097	O
capillary	1098	1107	B-Tissue
length	1108	1114	O
density	1115	1122	O
,	1122	1123	O
VEGF	1124	1128	B-Gene_or_gene_product
mRNA	1129	1133	O
increased	1134	1143	O
greater	1145	1152	O
than	1153	1157	O
2	1158	1159	O
-	1159	1160	O
fold	1160	1164	O
and	1165	1168	O
then	1169	1173	O
declined	1174	1182	O
to	1183	1185	O
control	1186	1193	O
levels	1194	1200	O
after	1201	1206	O
3	1207	1208	O
weeks	1209	1214	O
of	1215	1217	O
treatment	1218	1227	O
.	1227	1228	O

VEGF	1229	1233	B-Gene_or_gene_product
protein	1234	1241	O
was	1242	1245	O
higher	1246	1252	O
in	1253	1255	O
alinidine	1256	1265	B-Drug_or_compound
-	1265	1266	O
treated	1266	1273	O
rats	1274	1278	B-Organism
than	1279	1283	O
in	1284	1286	O
controls	1287	1295	O
after	1296	1301	O
2	1302	1303	O
weeks	1304	1309	O
and	1310	1313	O
increased	1314	1323	O
further	1324	1331	O
after	1332	1337	O
3	1338	1339	O
weeks	1340	1345	O
of	1346	1348	O
treatment	1349	1358	O
.	1358	1359	O

Injection	1360	1369	O
of	1370	1372	O
VEGF	1373	1377	B-Gene_or_gene_product
-	1377	1378	O
neutralizing	1378	1390	O
antibodies	1391	1401	O
over	1402	1406	O
a	1407	1408	O
2	1409	1410	O
-	1410	1411	O
week	1411	1415	O
period	1416	1422	O
completely	1423	1433	O
blocked	1434	1441	O
alinidine	1442	1451	B-Drug_or_compound
-	1451	1452	O
stimulated	1452	1462	O
angiogenesis	1463	1475	O
.	1475	1476	O

In	1477	1479	O
contrast	1480	1488	O
,	1488	1489	O
bFGF	1490	1494	B-Gene_or_gene_product
mRNA	1495	1499	O
was	1500	1503	O
not	1504	1507	O
altered	1508	1515	O
by	1516	1518	O
alinidine	1519	1528	B-Drug_or_compound
treatment	1529	1538	O
.	1538	1539	O

These	1540	1545	O
data	1546	1550	O
suggest	1551	1558	O
that	1559	1563	O
VEGF	1564	1568	B-Gene_or_gene_product
plays	1569	1574	O
a	1575	1576	O
key	1577	1580	O
role	1581	1585	O
in	1586	1588	O
the	1589	1592	O
angiogenic	1593	1603	O
response	1604	1612	O
that	1613	1617	O
occurs	1618	1624	O
with	1625	1629	O
chronic	1630	1637	O
bradycardia	1638	1649	O
.	1649	1650	O

The	1651	1654	O
mechanism	1655	1664	O
underlying	1665	1675	O
this	1676	1680	O
VEGF	1681	1685	B-Gene_or_gene_product
-	1685	1686	O
associated	1686	1696	O
angiogenesis	1697	1709	O
may	1710	1713	O
be	1714	1716	O
an	1717	1719	O
increase	1720	1728	O
in	1729	1731	O
stretch	1732	1739	O
due	1740	1743	O
to	1744	1746	O
enhanced	1747	1755	O
diastolic	1756	1765	O
filling	1766	1773	O
.	1773	1774	O

